© 2014 American Association for Clinical Chemistry LDL cholesterol (LDL-C) 3 is an important modifiable risk factor for atherosclerotic cardiovascular disease (1, 2 ) . However, it is primarily a calculated measure via the Friedewald equation and not measured directly. The Friedewald equation uses total cholesterol (TC), HDL cholesterol (HDL-C), and triglycerides (TG) to calculate LDL-C [LDL-C ϭ TC Ϫ HDL-C Ϫ (TG/5)]. Data advocating other LDL-C quantitative methods have suggested that this calculation [termed in this manuscript as Friedewald calculated LDL-C (LDL-C F )] misclassifies cardiovascular risk in many patients, particularly those with hypertriglyceridemia (3) (4) (5) (6) . Misclassification has been attributed to the TG/5 ratio used in the Friedewald equation, which represents an estimation of VLDL-C based on the average ratio of TG:cholesterol present in VLDL lipoproteins. Inaccuracies in LDL-C F at TG Ͼ400 mg/dL were acknowledged by Friedewald and colleagues in their original validation (7 ) and later proven by DeLong et al. (8 ) .
A recent study reported by Martin et al. has advocated use of a newly derived equation to estimate LDL-C that is intended to correct for this limitation in the Friedewald calculation and improve LDL-C estimation even when TG values are Ͻ400 mg/dL (9 ) . The novel LDL-C (referred to here as LDL-C N ) is calculated using an adjustable factor empirically determined on the basis of an individual patient's TG and non-HDL-C; this equation was derived using a large cohort of patients with LDL-C measured by the vertical autoprofile (VAP) method. Use of LDL-C N improved concordance over the Friedewald equation compared to measured LDL-C, particularly in patients with low LDL-C values [LDL-C Ͻ70 mg/dL (Ͻ1.8 mmol/L)]. However, changing longstanding approaches in a consistent manner across the global healthcare system might not be an easy task. Thus, advocacy for adoption of new techniques requires independent verification in multiple data sets, particularly when a variety of laboratory methods are used, and the magnitude of the benefit must be compelling. Accordingly, we evaluated the performance of the LDL-C N estimation method compared to the Friedewald equation method in an independent patient population in which LDL-C was measured by the gold standard ␤-quantification reference method (LDL-C ␤Q ).
Materials and Methods
All data were accessed in compliance with the Mayo Clinic Institutional Review Board. Retrospective analysis of lipoprotein metabolism profiles between 2003 and 2013 identified 23 055 individuals with LDL-C ␤Q and TG Ͻ400 mg/dL. All samples were collected after a minimum of 8 h fasting. Serum TC and TG were measured on a Roche Cobas c501 (Roche Diagnostics). HDL-C, LDL-C ␤Q , and VLDL-C concentrations were determined as described previously (10 ) . Briefly, 1 mL of serum was ultracentrifuged for 15 h at 75 000g. The upper layer (containing chylomicrons and VLDL) and lower layer (containing HDL and LDL) were separated and transferred to unique aliquot tubes. Each layer was analyzed for cholesterol and TG. HDL-C was determined following selective precipitation of LDL from the lower layer using a mixture of magnesium chloride and dextran sulfate. LDL-C ␤Q is calculated as [(lower layer cholesterol) Ϫ (HDL-C)] and VLDL-C is defined as [(upper layer cholesterol) Ϫ (chylomicron cholesterol)]. The analytical performance of these lipid measurements in our laboratory is directly certified by the CDC Lipid Standardization Program. Interassay precision was determined in serum by repeat measurement daily for 20 days. The CV for TC was 1.8% at 93 mg/dL, for HDL-C was 2.4% at 43 mg/dL, and for TG was 2.7% at 85 mg/dL. LDL-C ␤Q precision was determined by repeat analysis (n ϭ 37) of a pooled serum sample with mean LDL-C of 109 mg/dL (SD, 4.2 mg/dL; %CV, 3.9%). Non-HDL-C was calculated as (TC Ϫ HDL-C). The LDL-C F was: LDL-C F ϭ (TC Ϫ HDL-C) Ϫ (TG/ 5), and the novel method was calculated as: LDL-C N ϭ (TC Ϫ HDL-C) Ϫ (TG / X), where X is an adjustable factor based on the 180-cell method described by Martin et al. (9 ) . Concordance in classification by the National Cholesterol Education Program Adult Treatment Panel III guideline cutoffs (11 ) was defined as the number of estimated LDL-C values appropriately classified relative to the number of measured LDL-C values classified in each group using the reference method as the gold standard. (To convert TC, HDL-C, LDL-C, and VLDL-C to mmol/L, multiply by 0.0259; for TG multiply by 0.0113.) Statistical analyses were performed using JMP software (SAS Inc.). Statistical significance was defined as a P value Ͻ0.0001.
Results
Our cohort was predominantly middle-aged individuals [median 53 years; interquartile range (IQR) 40 -64] with 9% of patients Ͻ18 years of age (Table 1) . Overall, TG was 20% higher (median, 143 mg/dL; IQR, 94 -234 mg/dL) and HDL-C was 20% lower (median, 43 mg/ dL; IQR, 35-53 mg/dL) in our population than in the previously published derivation cohort (9 ) . The LDL-C N values were based on empirical TG:VLDL-C ratios ranging from 3.1 to 11.9 assigned according to TG and non-HDL-C strata in a derivation cohort (9 ) . Analyzing our cohort in a similar manner, we identified a range of TG:VLDL-C ratios from 3.0 to 12.2 with a median TG:VLDL-C of 5.8 (see Table 1 in the Data Supplement that accompanies the online version of this report at http://www.clinchem.org/content/vol60/ issue12). The median TC, non-HDL-C, and LDL-C ␤Q concentrations were within 10% of the previously published derivation cohort (Table 1) . Overall, LDL-C F underestimated LDL-C ␤Q , whereas LDL-C N tended to overestimate LDL-C ␤Q . The median LDL-C ␤Q was 110 mg/dL (IQR 87-139), the median LDL-C F was significantly lower at 108 mg/dL (IQR 83-138; P Ͻ 0.0001), and the median LDL-C N was significantly higher at 112 mg/dL (IQR 88 -141; P Ͻ 0.0001; Fig. 1 ). The median difference between LDL-C F and LDL-C ␤Q for all samples was Ϫ3 mg/dL (IQR, Ϫ8 to 3) and the median difference for LDL-C N was 0 mg/dL (IQR CI, Ϫ5 to 6).
Both estimation methods significantly deviated from the reference method when LDL-C ␤Q was Ͻ70 mg/dL.
The median difference for LDL-C F was Ϫ4 mg/dL (IQR, Ϫ9 to 0) in this category compared to Ϫ1 mg/dL (IQR, Ϫ5 to 4) for LDL-C N . Consequently, the LDL-C N method calculated fewer negative LDL-C concentrations compared to the LDL-C F method (1 vs 9 patients, respectively).
Concordance between estimated LDL-C and LDL-C ␤Q according to guideline-recommended cutoffs (11 ) of 70, 100, 130, 160, and 190 mg/dL was similar between the 2 estimations. LDL-C F correctly classified 17726 (77%) patients, compared to LDL-C N , which correctly classified 17914 (78%) patients (Table 2 ). Most misclassified patients were within 1 NCEP category of LDL-C ␤Q ; only 88 LDL-C F and 115 LDL-C N patients were misclassified by 2 or more NCEP categories.
In considering the implications to patient care, it is important to note that the current standard of practice is not the gold standard LDL-C ␤Q , but rather LDL-C F . To account for this we performed a series of analyses in which the estimated value was considered the reference (Table 3) . LDL-C F was marginally more concordant compared to LDL-C N when LDL-C was Ͼ100 mg/dL. Concordance was significantly higher for LDL-C N compared to LDL-C F when LDL-C was Ͻ100 mg/dL (P Ͻ 0.001). The greatest difference in concordance between the 2 estimations was observed in patients with LDL-C ␤Q Ͻ70 mg/dL. In this category, LDL-C F correctly classified 2306 patients and LDL-C N correctly classified 2089 patients. However, LDL-C F classified a total of 3239 patients with values Ͻ70 mg/dL whereas LDL-C N classified only 2474 patients in this category, providing relative concordances of 71.2% and 84.4% for LDL-C F and LDL-C N , respectively, if the initial classification were defined by the estimated value (Table 3) .
Our final analysis assessed the changes that clinicians would expect to see in patient LDL-C values if the novel method were to be implemented in routine prac- Median LDL-C is shown for each method according to guideline categories as determined by LDL-C ␤Q . I bars are IQR. Table 2 ). The largest changes would be seen in patients with LDL-C F Ͻ100 mg/dL, for which Ͼ20% of patients were grouped in a higher NCEP category by LDL-C N compared to LDL-C F .
Discussion
In the present study, we compared both the Friedewald and a novel estimated LDL-C against LDL-C ␤Q . In contrast to the prior study, which relied on validation of a subset of samples by ␤-quantification to allow the use of the vertical autoprofile method for LDL-C measurement, we had ␤-quantification values on the entire cohort. In our patient cohort, the novel method significantly overestimated LDL-C. Conversely, the Friedewald method tended to underestimate LDL-C. Several differences between the previously published cohort and the current study deserve acknowledgement. The median TG:VLDL-C ratio derived from our cohort is closer to the fixed factor of 6 proposed by Delong and colleagues (8 ) than the 5.2 ratio reported in the derivation cohort (9 ) . The higher median TG and lower median HDL-C suggest our cohort may have been enriched with dyslipidemic individuals compared to the published novel derivation cohort (9 ) .
In our cohort, the overall concordance between estimated and measured LDL-C according to NCEP guideline classification was similar for both methods, providing a 75%-80% certainty of correct classification regardless of the method used (Table 3) . However, as in the previous report, our study found significant differences in the equation performance at LDL-C Ͻ70 mg/dL. In this category, LDL-C N had a higher rate of concordance with LDL-C ␤Q and misclassified fewer patients compared to the Friedewald calculation. Although LDL-C F gave a higher absolute number of patients whose results were concordant with those of LDL-C ␤Q in the LDL-C Ͻ70 mg/dL category, the overall percentage of concordant values was lower, and the LDL-C F gave an increased number of false positives. Consequently, certainty of correct classification as Ͻ70 mg/dL is only 71% for the Friedewald method compared to 84% for the novel method.
The novel method incrementally but significantly improves LDL-C estimation when compared to the Friedewald equation. In clinical decision-making, it is important to note that LDL-C is a single component among many factors that determine a patient's risk of cardiovascular disease. The issue of how to use LDL-C in clinical practice has been controversial. It is not our goal to extend the controversy in regard to the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines (12 ) , but simply to evaluate this novel method.
Recent ACC/AHA guidelines deemphasize titrating to specific LDL-C goals; however, specific LDL-C values are recommended as criteria for considering statins in 2 situations. First, patients with an LDL-C Ͼ190 mg/dL are considered a statin benefit group. Estimating LDL-C by the novel method had negligible effect on patients in this category compared to the Friedewald method. Second, patients with a risk estimate Ͼ7.5% and an LDL-C between 70 and 189 mg/dL are considered a statin benefit group. According to our cohort, adoption of the novel method would place 14% of patients in a higher LDL-C NECP classification (see online Supplemental Table 2 ). Most of the recategorization would occur for patients with an LDL-C F of Ͻ70 mg/dL, leading to 25% fewer patients grouped in this category. The benefit of using the novel calculation is measurable yet incremental. Changing a calculation is a simple matter in the modern laboratory. However, the Friedewald method is well established and is likely the most universally adopted and standardized calculation in laboratory medicine. It remains to be discerned if the benefits of the novel method justify its widespread adoption.
